Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has made five new appointments to its scientific team, to support and accelerate its R&D.
Moritz Haneklaus PhD joins as Senior Scientist, Carmen Rodrigue-Seoane PhD as Scientist, with Chantell Payton PhD and Conor Poland PhD joining as Associate Scientists, and Sadie Kemp BSc as Senior Research Technician. Moritz will be based in Cambridge and will utilise his deep immunology expertise to support progression of the company’s discovery portfolio and development of novel cell-based assays. He brings 10 years molecular immunology experience to the company with international experience gained in the UK, Ireland, Sweden and Germany.
Carmen, Conor, and Sadie will be based at Macomics’ Edinburgh site and Chantell at the Cambridge site. Together they bring over 40 years combined research experience to the company, with specialisms including complex cellular models, cellular and molecular biology, functional genomics, and cancer biomarker discovery.
This expansion follows Macomics’ follow-on financing of £4.24 million announced in July. It is developing precision medicines to modulate macrophages for the treatment of cancer. The company is progressing a diversified portfolio of therapies targeting disease specific tumour associated macrophages (‘TAMs’) towards the clinic. Its target discovery platform enables identification and validation of novel macrophage therapeutic targets and is based on its deep understanding of macrophage biology.
Commenting on the expansion Dr Luca Cassetta, VP Immunology and co-founder who joined the company full time from his academic role said:
“I welcome our new colleagues to the team. Each brings valuable experience as we progress our early-stage antibody programs towards the clinic, expand our portfolio, and further invest in our target discovery technology.”
Macomics now employs 13 across its sites on the Cambridge Science Park and within Edinburgh University and will expand further in the coming months.
Dr Steve Myatt, CEO of Macomics added:
Our vision is to become a leading immuno-oncology company pioneering macrophage-based therapies for the treatment of cancer. These new appointments reflect our strategy to build a world-class team across all functions and support us in the delivery of this vision.
The full press release is available here.